These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15076720)

  • 1. Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector.
    Azzouz M; Ralph S; Wong LF; Day D; Askham Z; Barber RD; Mitrophanous KA; Kingsman SM; Mazarakis ND
    Neuroreport; 2004 Apr; 15(6):985-90. PubMed ID: 15076720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
    Connor B
    Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model.
    Dowd E; Monville C; Torres EM; Wong LF; Azzouz M; Mazarakis ND; Dunnett SB
    Eur J Neurosci; 2005 Nov; 22(10):2587-95. PubMed ID: 16307601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
    Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
    Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
    Lapchak PA; Araujo DM; Hilt DC; Sheng J; Jiao S
    Brain Res; 1997 Nov; 777(1-2):153-60. PubMed ID: 9449424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
    Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P
    Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
    Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
    Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.
    Bilang-Bleuel A; Revah F; Colin P; Locquet I; Robert JJ; Mallet J; Horellou P
    Proc Natl Acad Sci U S A; 1997 Aug; 94(16):8818-23. PubMed ID: 9238061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
    Georgievska B; Kirik D; Rosenblad C; Lundberg C; Björklund A
    Neuroreport; 2002 Jan; 13(1):75-82. PubMed ID: 11924898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.
    Do Thi NA; Saillour P; Ferrero L; Dedieu JF; Mallet J; Paunio T
    Gene Ther; 2004 May; 11(9):746-56. PubMed ID: 14724667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
    Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
    Du Y; Zhang X; Tao Q; Chen S; Le W
    Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
    Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
    Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector.
    Georgievska B; Jakobsson J; Persson E; Ericson C; Kirik D; Lundberg C
    Hum Gene Ther; 2004 Oct; 15(10):934-44. PubMed ID: 15585109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease.
    Yasuhara T; Shingo T; Muraoka K; Kobayashi K; Takeuchi A; Yano A; Wenji Y; Kameda M; Matsui T; Miyoshi Y; Date I
    J Neurosurg; 2005 Jan; 102(1):80-9. PubMed ID: 15658100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.
    Drinkut A; Tereshchenko Y; Schulz JB; Bähr M; Kügler S
    Mol Ther; 2012 Mar; 20(3):534-43. PubMed ID: 22086235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF.
    McBride JL; Kordower JH
    Prog Brain Res; 2002; 138():421-32. PubMed ID: 12432782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.